Inpatient with severe progressive osseous heteroplasia Everolimus (m-Tor inhibitor) ↓bone markers but showed no clinical benefit. M. Cebey-López et al. Front Pediatr 22 Nov2022 https://t.co/r0EO7CtSjc …her monochorionic twin sister almost asymptomatic http
RT @fedemartinon: Everolimus reduced bone turnover markers but showed no clinical benefit in a patient with severe progressive osseous hete…
RT @fedemartinon: Everolimus reduced bone turnover markers but showed no clinical benefit in a patient with severe progressive osseous hete…
RT @fedemartinon: Everolimus reduced bone turnover markers but showed no clinical benefit in a patient with severe progressive osseous hete…